Enabling Future Medicines
Australia's most comprehensive bioanalytical laboratory offers a full suite of pharmacokinetic and pharmacodynamic assays for your early-phase clinical studies.
Our global footprint allows you to use the Australian advantage to expedite your Phase 1 study & expand into Phase 2 with our global BioAgilytix laboratories.
Explore BioAgilytix Global Team360biolabs Comprehensive Services
Infectious Diseases
At 360biolabs, we value science-driven excellence, innovation, quality, and reliable bioanalytical testing. Our passion for the science of assay development, biomarker analysis, and pharmacokinetic assessments drives our delivery of our wide range of comprehensive services.
Advancing
Health Globally
BioAgilytix's state-of-the-art laboratories extend to 3 countries and 6 facilities. We support all phases of drug development with local expertise and global resources. Experience world-class bioanalytical excellence that accelerates your breakthroughs.
Australian Advantage
Accelerating Your Global Clinical Research
Speed
Australia offers a fast and pragmatic regulatory environment for early-phase clinical (no IND required).
Cost
The Australian government offers an attractive R&D tax incentive of 43.5% to eligible companies.
Quality
Australia is an OECD country and a member of the OECD Mutual Acceptance of Data (MAD) system. Data from studies conducted in Australia can be used to support international regulatory applications.
Decade of Enabling Future Medicines
Discover our 10 series: a Decade of Science, throughout the year we will be highlighting 360biolabs journey of science-driven innovation and bioanalytical excellence, supporting clients in a wide range of therapeutic areas with our comprehensive capabilities.
Stay Connected
Stay connected with us on LinkedIn and see service updates, events, seminars, and company updates.
